Biotechnology

https://techpapersworld.com/wp-content/uploads/2024/12/Rare-Disease-Consulting-1280x720.jpg

BiotechnologyRare Disease Consulting: Explore How to Address the Low Prevalence and High Outstanding Therapeutics Needs, and Stay Ahead by Understanding the Gaps in the Rare Diseases Market with DelveInsight

At DelveInsight, we take pride in being a leading provider of pharma competitive intelligence and consulting solutions, specializing in the rare diseases domain. With over 350 epidemiology-based market reports published, our experienced team brings deep expertise and precision to navigating the complexities of the orphan disease market. We recognize the scarcity of published data on rare patient populations, the high unmet needs, and the challenges of inaccurate diagnoses. Over the years, we have built an extensive...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/12/Roches-Phase-IIb-Study-of-Prasinezumab--1280x720.jpg

BiotechnologyRoche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

Prothena Corporation plc (NASDAQ:PRTA), today announced results from the Phase IIb PADOVA study conducted by partner Roche investigating prasinezumab in 586 people with early-stage Parkinson’s disease, treated for a minimum of 18 months while on stable symptomatic treatment. Prasinezumab showed potential clinical effect in the primary endpoint of time to confirmed motor progression with a HR=0.84 [0.69-1.01] and p=0.0657. The effect of prasinezumab was more pronounced in a pre-specified analysis in the population treated with...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Astellas-and-Sangamo-Therapeutics-1280x720.jpg

BiotechnologyAstellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced they have entered into a license agreement allowing Astellas to leverage Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates. The agreement grants Astellas a worldwide exclusive license to utilize the STAC-BBB capsid for one target, with the right to add...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Bridge-to-Life-Acquires-1280x720.jpg

BiotechnologyBridge to Life Acquires VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A.

Bridge to Life Ltd., a leader in organ preservation solutions and perfusion technology, has acquired the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A.. The agreement also includes exclusive global trademark rights and the ability to register the VitaSmart™ name worldwide. This acquisition marks a significant milestone in Bridge to Life’s efforts to advance transplant medicine. Over 5,0001 successful liver perfusions have been conducted globally using Hypothermic Oxygenated Perfusion (HOPE) in combination with the VitaSmart™...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Novo-Nordisk-Foundation--1280x720.jpg

BiotechnologyNovo Nordisk Foundation grants €134.1 million to establish the Biotechnology Research Institute for the Green Transition (BRIGHT) in Denmark

Our daily lives are full of products and processes based on fossil materials, or created using fossil energy sources such as oil and gas. To make significant progress in the green transition, we need to become much better at harnessing the power of bioproduction – biologically based production solutions that can replace fossil energy sources and materials. These are also known as biosolutions. This is the aim of the new initiative at the Technical University of Denmark (DTU):...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/12/Sensorion-Reports-Data-in-the-Audiogene-1280x720.jpg

BiotechnologySensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, announced today latest data updates confirming the safety of SENS-501 in the two first patients injected in the Company’s Audiogene study. This is a Phase 1/2 clinical trial evaluating SENS-501 in patients aged 6 to 31 months and naïve of cochlear implant, who are suffering from a specific form of congenital deafness...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/12/Soilytix-Pioneers-Breakthrough-in-Soil-Microbiome-1280x720.jpg

BiotechnologySoilytix Pioneers Breakthrough in Soil Microbiome Research for Global Crop Yield Predictions

Soilytix GmbH, a leading innovator in soil microbiome analytics, announces a groundbreaking study recently published in Science of the Total Environment. The research, titled “Local Microbial Yield-Associating Signatures Largely Extend to Global Differences in Plant Growth,” showcases how machine learning applied to soil microbiome data can revolutionize crop yield predictions on a global scale. “Our findings indicate a globally conserved set of soil bacteria that are useful in predicting plant growth between sites” The study highlights...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Promise-Bio-Emerges-from-1280x720.jpg

BiotechnologyPromise Bio Emerges from Stealth with $8.3M Seed Investment to Transform Precision Medicine for Immune-Mediated Diseases

Promise Bio, a startup transforming immune-mediated disease treatment with advanced precision medicine solutions, today announced its emergence from stealth with an $8.3 million seed investment. This funding will accelerate the development of Promise Bio’s computational platform, which uses epiproteomics and artificial intelligence to predict patient treatment responses and support drug research and development. “Current biological treatments for autoimmune diseases don’t work in all patients, with only 30-40% of patients achieving significant remission. At Promise Bio, our mission...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/12/Biocytogen-Announces-Adcendo-ApS-Exercises-1280x720.jpg

BiotechnologyBiocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that Adcendo ApS (“Adcendo”), a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, has exercised its option under a research, option and license agreement to utilize Biocytogen’s fully human antibodies to further expand its ADC pipeline. “We are excited to deploy...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Nona-Biosciences-Announces-1280x720.jpg

BiotechnologyNona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers

Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to ITM), today announced a research collaboration and license agreement to discover next-generation T-cell engagers (“TCEs”) with Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company based in San Diego and focused on becoming the leader in advancing TCEs for autoimmune diseases. Under the terms of the agreement, Nona Biosciences is eligible to receive up to $320 million, including an upfront payment and potential milestone payments....

Newer Posts

Older Posts